{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:12:10Z","timestamp":1787807530491,"version":"build-2784847793"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bcp.2024.116683","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T07:33:51Z","timestamp":1732692831000},"page":"116683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["miRNA signatures affecting the survival outcome in distant metastasis of triple-negative breast cancer"],"prefix":"10.1016","volume":"231","author":[{"given":"Acharya","family":"Balkrishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Bishayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Prem","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9159-960X","authenticated-orcid":false,"given":"Anupam","family":"Bishayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116683_b0005","unstructured":"World Health Organization. Accessed on 25th April 2024. https:\/\/www.who.int\/news-room\/factsheets\/detail\/breastcancer#:\u223c:text=In%202022%2C%20there%20were%202.3,increasing%20rates%20in%20later%20life."},{"key":"10.1016\/j.bcp.2024.116683_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Soerjomataram, I. Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"The Breast"},{"key":"10.1016\/j.bcp.2024.116683_b0015","doi-asserted-by":"crossref","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2024.116683_b0020","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0025","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2174\/1568009621666210908113010","article-title":"Unveiling novel therapeutic drug targets and Prognostic markers of triple negative breast cancer","volume":"21","author":"Balkrishna","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2024.116683_b0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fonc.2020.00014","article-title":"A risk stratification model for predicting overall survival and surgical benefit in triple-negative breast cancer patients with de novo distant metastasis","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0035","doi-asserted-by":"crossref","DOI":"10.1002\/prm2.12107","article-title":"Patterns of distant metastases in patients with triple\u2010negative breast cancer\u2014A population\u2010based study","volume":"12","author":"Gao","year":"2023","journal-title":"Precis. Med. Sci."},{"key":"10.1016\/j.bcp.2024.116683_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"133","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116683_b0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-017-0742-4","article-title":"Factors involved in cancer metastasis: a better understanding to \u201cseed and soil\u201d hypothesis","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2011.05.002","article-title":"Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype","volume":"11","author":"Theriault","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0055","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-016-5631-3","article-title":"Evaluation of local and distant recurrence patterns in patients with triple-negative breast cancer according to age","volume":"24","author":"Radosa","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0060","doi-asserted-by":"crossref","DOI":"10.4149\/neo_2013_038","article-title":"Distant metastasis in triple-negative breast cancer","volume":"60","author":"Tseng","year":"2013","journal-title":"Neoplasma"},{"key":"10.1016\/j.bcp.2024.116683_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2012.04.019","article-title":"Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (< 65) and elderly (\u226565) patients","volume":"48","author":"K\u00f6nigsberg","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/1568009620999201103201626","article-title":"Potential role of miRNA in metastatic cascade of triple-negative breast cancer","volume":"21","author":"Balkrishna","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.bcp.2024.116683_b0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.seminoncol.2020.05.005","article-title":"The evolving management of metastatic triple negative breast cancer","volume":"47","author":"Malhotra","year":"2020","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0080","article-title":"Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0085","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT05035745?term=NCT05035745&rank=1."},{"key":"10.1016\/j.bcp.2024.116683_b0090","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT06067061?cond=Triple%20Negative%20Breast%20Cancer&rank=3."},{"key":"10.1016\/j.bcp.2024.116683_b0095","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT05973864?cond=Triple%20Negative%20Breast%20Cancer&rank=7."},{"key":"10.1016\/j.bcp.2024.116683_b0100","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT03692689?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=11."},{"key":"10.1016\/j.bcp.2024.116683_b0105","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT04489940?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=12."},{"key":"10.1016\/j.bcp.2024.116683_b0110","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT03310957?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=13."},{"key":"10.1016\/j.bcp.2024.116683_b0115","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT04191135?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=14."},{"key":"10.1016\/j.bcp.2024.116683_b0120","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT02720185?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=16."},{"key":"10.1016\/j.bcp.2024.116683_b0125","unstructured":"National Library of Medicine. Accessed on 10th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT02124902?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=17."},{"key":"10.1016\/j.bcp.2024.116683_b0130","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT02622074?cond=Triple%20Negative%20Breast%20Cancer&page=2&rank=18."},{"key":"10.1016\/j.bcp.2024.116683_b0135","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT04251533."},{"key":"10.1016\/j.bcp.2024.116683_b0140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116683_b0145","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT03036488?cond=Triple%20Negative%20Breast%20Cancer&page=3&rank=21."},{"key":"10.1016\/j.bcp.2024.116683_b0150","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT03838367?cond=Triple%20Negative%20Breast%20Cancer&page=3&rank=23."},{"key":"10.1016\/j.bcp.2024.116683_b0155","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT03997123?cond=Triple%20Negative%20Breast%20Cancer&page=3&rank=24."},{"key":"10.1016\/j.bcp.2024.116683_b0160","unstructured":"National Library of Medicine. Accessed on 11th March 2024: https:\/\/clinicaltrials.gov\/study\/NCT02977468?cond=Triple%20Negative%20Breast%20Cancer&page=3&rank=29."},{"key":"10.1016\/j.bcp.2024.116683_b0165","unstructured":"National Library of Medicine. Accessed on 10th June 2024: Retrieved from https:\/\/clinicaltrials.gov\/study\/NCT05112536?cond=Triple%20Negative%20Breast%20Cancer%20TNBC&intr=CDK4%2F6%20inhibitors&rank=2&tab=results."},{"key":"10.1016\/j.bcp.2024.116683_b0170","unstructured":"National Cancer Institute. Accessed on 17th June 2024: https:\/\/portal.gdc.cancer.gov\/analysis_page?app=."},{"key":"10.1016\/j.bcp.2024.116683_b0175","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128272489231124095922","article-title":"Tumor suppressive role of microRNAs in triple negative breast cancer","author":"Balkrishna","year":"2023","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bcp.2024.116683_b0180","first-page":"5069","article-title":"MicroRNAs, a subpopulation of regulators, are involved in breast cancer progression through regulating breast cancer stem cells","volume":"14","author":"Fan","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2024.116683_b0185","doi-asserted-by":"crossref","first-page":"6755","DOI":"10.2147\/CMAR.S199027","article-title":"MicroRNA-206 inhibits metastasis of triple-negative breast cancer by targeting transmembrane 4 L6 family member 1","author":"Fan","year":"2019","journal-title":"Cancer Manag Res."},{"key":"10.1016\/j.bcp.2024.116683_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0988-0","article-title":"MCT-1\/miR-34a\/IL-6\/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer","volume":"18","author":"Weng","year":"2019","journal-title":"Mol.cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0195","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4048\/jbc.2018.21.e59","article-title":"The open issues regarding cyclin-dependent kinase 4\/6 inhibitors in the management of advanced breast cancer","volume":"21","author":"Yang","year":"2018","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0200","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12087","article-title":"Circulating microRNAs and their role in the immune response in triple\u2013negative breast cancer","volume":"20","author":"Pi\u00f1a-S\u00e1nchez","year":"2020","journal-title":"Oncol. Lett."},{"issue":"41451","key":"10.1016\/j.bcp.2024.116683_b0205","article-title":"MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116683_b0210","first-page":"519","article-title":"MicroRNA-200c inhibits the metastasis of triple-negative breast cancer by targeting ZEB2, an epithelial-mesenchymal transition regulator","volume":"50","author":"Chen","year":"2020","journal-title":"Ann.Clin.Lab.Sci."},{"issue":"19645","key":"10.1016\/j.bcp.2024.116683_b0215","article-title":"Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer","volume":"8","author":"Bhardwaj","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116683_b0220","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/cgt.2016.27","article-title":"MicroRNA-145 functions as a tumor suppressor by targeting matrix metalloproteinase 11 and Rab GTPase family 27a in triple-negative breast cancer","volume":"23","author":"Tang","year":"2016","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bcp.2024.116683_b0225","article-title":"Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0230","article-title":"Prognostic significance of molecular subtype, metastatic site and primary tumor surgery for survival in primary metastatic breast cancer: A SEER-based study","volume":"100","author":"Li","year":"2021","journal-title":"Medicine"},{"issue":"1141\u20131157","key":"10.1016\/j.bcp.2024.116683_b0235","article-title":"Mechanistic insight of drug resistance with special focus on iron in estrogen receptor positive breast cancer","volume":"15","author":"Mittal","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bcp.2024.116683_b0240","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.3390\/jcm11206021","article-title":"Current therapeutic strategies for metastatic triple-negative breast cancer: from pharmacists\u2019 perspective","volume":"11","author":"Li","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2024.116683_b0245","article-title":"Neoadjuvant VS adjuvant chemotherapy in patients with locally advanced breast cancer; a retrospective cohort study","volume":"84","author":"Akbari","year":"2022","journal-title":"Ann. Med. Sur."},{"key":"10.1016\/j.bcp.2024.116683_b0250","article-title":"Current approaches in treatment of triple-negative breast cancer","volume":"12","author":"Wahba","year":"2015","journal-title":"Cancer Bio. Med."},{"key":"10.1016\/j.bcp.2024.116683_b0255","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clon.2018.09.006","article-title":"Outcomes for patients with non-metastatic triple-negative breast cancer in New Zealand","volume":"31","author":"James","year":"2019","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-016-3757-4","article-title":"Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort study","volume":"156","author":"Van Roozendaal","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2024.116683_b0265","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","article-title":"Response to neoadjuvant therapyand long-term survival in patients with triple-negative breast cancer","volume":"26","author":"Liedtke","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-553","article-title":"The treatment and survival of patients with triple negative breast cancer in a London population","volume":"3","author":"Pal","year":"2014","journal-title":"Springer plus"},{"key":"10.1016\/j.bcp.2024.116683_b0275","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.surge.2016.10.001","article-title":"Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer","volume":"15","author":"Joyce","year":"2017","journal-title":"Surgeon"},{"key":"10.1016\/j.bcp.2024.116683_b0280","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/fon-2020-1021","article-title":"Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer","volume":"17","author":"Skinner","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jfma.2021.04.028","article-title":"Treatment-associated survival outcomes in real-world patients with de novo metastatic triple-negative breast cancer: Age as a significant treatment effect-modifier","volume":"121","author":"Chung","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.bcp.2024.116683_b0290","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2174\/1389450124666230308154551","article-title":"Unveiling role of microRNAs in metastasizing triple negative breast cancer: from therapeutics to delivery","volume":"24","author":"Balkrishna","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bcp.2024.116683_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1210-4","article-title":"Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review","volume":"21","author":"Li","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0300","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.breast.2021.01.006","article-title":"Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program","volume":"56","author":"Cabel","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2024.116683_b0305","article-title":"233P Treatment pattern and outcomes for the first two lines of chemotherapy in patients diagnosed with metastatic triple-negative breast cancer, results from the Dutch SONABRE Registry","volume":"8","author":"Geurts","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.bcp.2024.116683_b0310","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx365.031","article-title":"What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?","volume":"28","author":"Bajaj","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0315","article-title":"Efficacy and safety of first-line treatment for metastatic triple-negative breast cancer: a network meta-analysis","author":"Shi","year":"2023","journal-title":"Cancer Path. Therapy"},{"key":"10.1016\/j.bcp.2024.116683_b0320","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.3390\/ijms22084072","article-title":"MicroRNAs and long noncoding RNAs as novel therapeutic targets in estrogen receptor-positive breast and ovarian cancers","volume":"22","author":"Barwal","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116683_b0325","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/curroncol29040189","article-title":"A pleiotropic role of long non-coding RNAs in the modulation of Wnt\/\u03b2-catenin and PI3K\/Akt\/mTOR signaling pathways in esophageal squamous cell carcinoma: implication in chemotherapeutic drug response","volume":"29","author":"Sharma","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0330","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2024.116683_b0335","doi-asserted-by":"crossref","DOI":"10.1038\/aps.2013.35","article-title":"Friend or foe: the role of microRNA in chemotherapy resistance","volume":"34","author":"Li","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bcp.2024.116683_b0340","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15607-y","article-title":"IGF-1-mediated PKM2\/\u03b2-catenin\/miR-152 regulatory circuit in breast cancer","volume":"7","author":"Wen","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0345","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0526-y","article-title":"Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management","volume":"17","author":"Van Schooneveld","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0350","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-021-07080-8","article-title":"MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A\/PGRN axis to prevent the epithelial-mesenchymal transition","volume":"49","author":"Wang","year":"2022","journal-title":"Mol. Bio. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0355","doi-asserted-by":"crossref","DOI":"10.18632\/aging.205051","article-title":"The oncogenic miR-429 promotes triple-negative breast cancer progression by degrading DLC1","volume":"15","author":"Li","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.bcp.2024.116683_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2020.06.003","article-title":"Dual regulation of miR-34a and Notch signaling in triple-negative breast cancer by antibody\/miRNA nanocarriers","volume":"21","author":"Valcourt","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bcp.2024.116683_b0365","article-title":"Clinical value of circulating miR-6861-5p in the diagnosis and treatment of breast cancer","author":"Yuan","year":"2018","journal-title":"Chin. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0370","article-title":"MiR-1976 knockdown promotes epithelial\u2013mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2024.116683_b0375","article-title":"miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN","volume":"9","author":"Fang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.bcp.2024.116683_b0380","doi-asserted-by":"crossref","DOI":"10.2147\/OTT.S127723","article-title":"miR-17 as a diagnostic biomarker regulates cell proliferation in breast cancer","author":"Yang","year":"2017","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bcp.2024.116683_b0385","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03192-4","article-title":"Unveiling the ups and downs of miR-205 in physiology and cancer: transcriptional and post-transcriptional mechanisms","volume":"11","author":"Ferrari","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2024.116683_b0390","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13010127","article-title":"The role of miRNAs in the prognosis of triple-negative breast cancer: a systematic review and meta-analysis","volume":"13","author":"Santana","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.bcp.2024.116683_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/medicina58101494","article-title":"The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the pathological response of breast cancer patients to neoadjuvant therapy","volume":"58","author":"Lisencu","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.bcp.2024.116683_b0400","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2021.13077","article-title":"MicroRNA\u2013100 inhibits breast cancer cell proliferation, invasion and migration by targeting FOXA1","volume":"22","author":"Xie","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2024.116683_b0405","article-title":"MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116683_b0410","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01059-5","article-title":"MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists","volume":"8","author":"Lv","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116683_b0415","doi-asserted-by":"crossref","DOI":"10.3390\/cells8121492","article-title":"MicroRNAs involved in carcinogenesis, prognosis, therapeutic resistance, and applications in human triple-negative breast cancer","volume":"8","author":"Ding","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2024.116683_b0420","article-title":"MicroRNA-590-3p inhibits invasion and metastasis in triple-negative breast cancer by targeting Slug","volume":"10","author":"Yan","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0425","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820977523","article-title":"miR-518a-3p suppresses triple-negative breast cancer invasion and migration through regulation of TMEM2","volume":"19","author":"Gan","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2024.116683_b0430","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.897731","article-title":"MiR-940 inhibited cell growth and migration in triple-negative breast cancer","volume":"22","author":"Hou","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bcp.2024.116683_b0435","doi-asserted-by":"crossref","DOI":"10.3390\/ncrna7030045","article-title":"Nanoliposomal delivery of microrna-203 suppresses migration of triple-negative breast cancer through distinct target suppression","volume":"7","author":"Song","year":"2021","journal-title":"Non-coding RNA"},{"key":"10.1016\/j.bcp.2024.116683_b0440","article-title":"HIF-1\u03b1\/Malat1\/miR-141 axis activates autophagy to increase proliferation, migration, and invasion in triple-negative breast cancer","volume":"23","author":"Xu","year":"2023","journal-title":"Curr. Cancer Drug Targ."},{"key":"10.1016\/j.bcp.2024.116683_b0445","article-title":"The miR-124-3p\/neuropilin-1 axis contributes to the proliferation and metastasis of triple-negative breast cancer cells and co-activates the TGF-\u03b2 pathway","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0450","article-title":"MiRNAs predict the prognosis of patients with triple negative breast cancer: a meta-analysis","volume":"12","author":"Liu","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116683_b0455","first-page":"3313","article-title":"Identification of dysregulated microRNAs associated with diagnosis and prognosis in triple\u2013negative breast cancer: an in silico study","volume":"41","author":"Fan","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0460","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.3390\/cancers12113298","article-title":"Modulatory role of microRNAs in triple negative breast cancer with basal-like phenotype","volume":"12","author":"Angius","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bcp.2024.116683_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-017-0865-y","article-title":"miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer","volume":"19","author":"Wang","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0470","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202205462","article-title":"Walking dead tumor cells for targeted drug delivery against lung metastasis of triple\u2010negative breast cancer","volume":"34","author":"Zhao","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bcp.2024.116683_b0475","article-title":"MicroRNA\u2013606 inhibits the growth and metastasis of triple\u2013negative breast cancer by targeting Stanniocalcin 1","volume":"51","author":"Choi","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/etm.2021.9666","article-title":"MicroRNA\u2013598 inhibits the growth of triple negative breast cancer cells by targeting JAG1","volume":"21","author":"Han","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2024.116683_b0485","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4048\/jbc.2014.17.2.143","article-title":"miR-205 and miR-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer","volume":"17","author":"Berber","year":"2014","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048692","article-title":"Validation of expression patterns for nine miRNAs in 204 lymph-node negative breast cancers","volume":"7","author":"Jonsdottir","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116683_b0495","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.12593","article-title":"Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells","volume":"7","author":"Taipaleenm\u00e4ki","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116683_b0500","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s11914-021-00677-9","article-title":"MicroRNAs and their roles in breast cancer bone metastasis","volume":"19","author":"Puppo","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-1059-y","article-title":"Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts","volume":"20","author":"Liu","year":"2018","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bcp.2024.116683_b0510","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/s41388-021-01654-3","article-title":"MiR-211 determines brain metastasis specificity through SOX11\/NGN2 axis in triple-negative breast cancer","volume":"40","author":"Pan","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116683_b0515","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1097\/RLU.0000000000003336","article-title":"Recurrent brain metastasis of triple negative breast cancer with high uptake in 68Ga-PSMA-11 PET\/CT","volume":"46","author":"Arslan","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.bcp.2024.116683_b0520","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1096\/fj.201800120R","article-title":"Novel prognostic and predictive microRNA targets for triple\u2010negative breast cancer","volume":"32","author":"Turashvili","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.bcp.2024.116683_b0525","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.humpath.2017.08.026","article-title":"Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer","volume":"68","author":"Jang","year":"2017","journal-title":"Hum.pathol."},{"key":"10.1016\/j.bcp.2024.116683_b0530","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/cas.13644","article-title":"MicroRNA\u2010493 is a prognostic factor in triple\u2010negative breast cancer","volume":"109","author":"Yao","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2024.116683_b0535","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1369\/0022155417702849","article-title":"The MicroRNA miR-210 is expressed by cancer cells but also by the tumor microenvironment in triple-negative breast cancer","volume":"65","author":"Bar","year":"2017","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.bcp.2024.116683_b0540","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fonc.2020.01371","article-title":"MicroRNA-27b-3p promotes tumor progression and metastasis by inhibiting peroxisome proliferator-activated receptor gamma in triple-negative breast cancer","volume":"10","author":"Shen","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116683_b0545","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1159\/000485785","article-title":"MiR-212-5p suppresses the epithelial-mesenchymal transition in triple-negative breast cancer by targeting Prrx2","volume":"44","author":"Lv","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"10.1016\/j.bcp.2024.116683_b0550","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.3390\/ijms21238905","article-title":"Novel miRNA targets and therapies in the triple-negative breast cancer microenvironment: an emerging hope for a challenging disease","volume":"21","author":"Qattan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116683_b0555","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41598-019-57094-3","article-title":"The prognostic and predictive potential of Ki-67 in triple-negative breast cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2024.116683_b0560","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.7150\/thno.46142","article-title":"A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse","volume":"10","author":"Hong","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2024.116683_b0565","first-page":"1","article-title":"Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer","volume":"14","author":"Avery-Kiejda","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2024.116683_b0570","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3349\/ymj.2017.58.4.697","article-title":"Low expression of circulating microRNA-34c is associated with poor prognosis in triple-negative breast cancer","volume":"58","author":"Zeng","year":"2017","journal-title":"Yonsei Med. J."},{"issue":"12188","key":"10.1016\/j.bcp.2024.116683_b0575","article-title":"miR-20b is up-regulated in brain metastases from primary breast cancers","volume":"6","author":"Ahmad","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2024.116683_b0580","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.drudis.2022.01.010","article-title":"Triple-negative breast cancer brain metastasis: an update on druggable targets, current clinical trials, and future treatment options","volume":"27","author":"Nakhjavani","year":"2022","journal-title":"Drug Discov.Today"},{"key":"10.1016\/j.bcp.2024.116683_b0585","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/15384047.2019.1595285","article-title":"MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer","volume":"20","author":"Wong","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2024.116683_b0590","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s10038-018-0510-3","article-title":"Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3","volume":"63","author":"Toda","year":"2018","journal-title":"J.hum.genet."},{"key":"10.1016\/j.bcp.2024.116683_b0595","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3892\/ol.2024.14565","article-title":"Role of microRNAs in triple\u2013negative breast cancer and new therapeutic concepts","volume":"28","author":"Yang","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bcp.2024.116683_b0600","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116683_b0605","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1021\/nn507465d","article-title":"Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy","volume":"9","author":"Devulapally","year":"2015","journal-title":"ACS Nano."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224006841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:43:35Z","timestamp":1733906615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224006841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":121,"alternative-id":["S0006295224006841"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116683","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"miRNA signatures affecting the survival outcome in distant metastasis of triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116683","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116683"}}